Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Capio in connection with the acquisition of the Nova clinics
Mandate

Vinge advises Capio in connection with the acquisition of the Nova clinics

February 26, 2018 M&A

Vinge has advised Capio, which is listed on Nasdaq Stockholm, in connection with the acquisition of the shares in the Nova clinics.

The Nova clinics primarily conduct healthcare operations at eight clinics in the southeast of Skåne and have certain operations within occupational health service and dental service. In 2017, the Nova clinics had a turnover of approximately MSEK 245 and had approximately 45 000 listed patients. The purchase price mechanism, which is based on Enterprise Value, amounts to MSEK 88. The acquisition is conditional upon the Swedish Competition Authority’s and Region Skåne’s approval.

Vinge’s team consisted of Anders Strid, Frida Bäckegren (project manager), Gabriella Fossum (LOU), Rebecka Maltenius (commercial property law), Lina André (employment law), Camilla Andersson (company registration assistant) as well as Pär Remenlid and Nils Alvång (both competition law).

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025